SCHEMBL16648680

SCHEMBL16648680

CCOC(=O)C1CCN(c2cc(C(F)(F)F)ccn2)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 1/20 0.54
FFAR4 Q5NUL3 1/20 0.53
CHRM4 P08173 1/20 0.51
L3MBTL1 Q9Y468 5/20 0.50
ADRB1 P08588 1/20 0.50
PPARG P37231 1/20 0.49
PPARD Q03181 1/20 0.49
PPARA Q07869 1/20 0.49
MAPT P10636 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PIK3CA P42336 1/20 0.48
FFAR1 O14842 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15286619 0.84 ALDH1A1 (0.52) CHRM4MAPTKDM4EALDH1A1PIK3CA
SCHEMBL1573375 0.83 HPGD (0.69) L3MBTL1KDM4E
SCHEMBL15578242 0.82 MAPT (0.54) L3MBTL1MAPTKDM4EALDH1A1PIK3CA
SCHEMBL29387438 0.82 MAPT (0.54) L3MBTL1MAPTKDM4EALDH1A1PIK3CA
SCHEMBL3254559 0.82 SHMT2 (0.61) MAPTKDM4EALDH1A1PIK3CA
SCHEMBL16648726 0.81 ALDH1A1 (0.58) HRH3L3MBTL1MAPTKDM4EALDH1A1
SCHEMBL7134998 0.81 KDM4E (0.67) HRH3FFAR4CHRM4ADRB1MAPT
SCHEMBL16648517 0.81 GPR119 (0.52) MAPTKDM4EALDH1A1
SCHEMBL15578227 0.80 ALDH1A1 (0.51) L3MBTL1MAPTKDM4EALDH1A1
SCHEMBL6506137 0.79 NOTUM (0.61) MAPTKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
EP-2862861-B1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-01-06 EP disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-9150575-B2 Piperidinylpyrazolopyridine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-10-06 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-06-04 US disclosed
EP-2862861-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2015-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152102-A1 PIPERIDINYLPYRAZOLOPYRIDINE DERIVATIVE LCAT, LPL, LCLAT1 HRH3 3681/4885FFAR4 497/4885CHRM4 4550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.